Welcome to the trials list!

Some tips to help get started:

  • Click on any trial title to view details, including trial sites, eligibility criteria, and our research about study drugs
  • If the list is long, use the search box and filters on the left to narrow down trials
  • Bookmark trials of interest by clicking the bookmark icon to the right of the trial title
Sign up to save your data! Arrow
Processing... Processing...

Clinical Trials for Other Solid Tumor

Search

Close
[Clear]

Filters

Location:
[Clear]
[Clear]

There are 397 active trials for advanced/metastatic other solid tumor. Click on a trial to see more information. Note that this list also includes some trials that are only for specific cancer types like lung cancer. To see trials customized to a patient, please select a patient above.

397 trials meet filter criteria.

Sort by:

No known activity More information High burden on patient More information
Sponsor: A2 Biotherapeutics Inc. (industry) Phase: 1/2 Start date: Nov. 12, 2024

HealthScout AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express EGFR and have lost HLA-A*02 expression, including types such as CRC, NSCLC, HNSCC, TNBC, and RCC, and tests A2B395, a logic-gated Tmod™ CAR T-cell therapy designed to selectively target these tumor cells while sparing healthy cells. Participants receive a preconditioning lymphodepletion regimen followed by a single intravenous dose of A2B395.

ClinicalTrials.gov ID: NCT06682793

No known activity More information High burden on patient More information
Sponsor: Olema Pharmaceuticals, Inc. (industry) Phase: 1 Start date: Dec. 16, 2024

HealthScout AI summary: This trial involves adult patients with advanced or metastatic ER+ HER2- breast cancer, castration-resistant prostate cancer, or non-small cell lung cancer, focusing on those who have exhausted available therapies; it investigates OP-3136, an oral small molecule inhibitor of lysine acetyltransferases 6A and 6B, for safety, pharmacokinetics, and preliminary efficacy.

ClinicalTrials.gov ID: NCT06784193

No known activity More information High burden on patient More information
Sponsor: Innate Pharma (industry) Phase: 1 Start date: Jan. 24, 2025

HealthScout AI summary: This trial involves patients with unresectable, locally advanced, or metastatic solid tumors expressing Nectin-4, who have exhausted other treatment options, receiving the investigational antibody-drug conjugate IPH4502, which targets Nectin-4 with unique epitope binding and an exatecan payload to enhance anti-tumor effects.

ClinicalTrials.gov ID: NCT06781983

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Nurix Therapeutics, Inc. (industry) Phase: 1 Start date: Sept. 29, 2021

HealthScout AI summary: This trial involves adult patients with advanced solid tumors or diffuse large B-cell lymphoma that are metastatic or unresponsive to standard treatments and evaluates the safety and efficacy of NX-1607, a CBL-B inhibitor, as monotherapy or in combination with paclitaxel.

ClinicalTrials.gov ID: NCT05107674

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Inhibrx Biosciences, Inc (industry) Phase: 1/2 Start date: Dec. 10, 2019

HealthScout AI summary: This trial evaluates the safety and maximum tolerated dose of INBRX-106, a hexavalent OX40 agonist antibody, both alone and in combination with pembrolizumab, in adult patients with locally advanced or metastatic solid tumors, including NSCLC, melanoma, and head and neck squamous cell carcinoma, who have progressed on standard therapies.

ClinicalTrials.gov ID: NCT04198766

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: OncoResponse, Inc. (industry) Phase: 1/2 Start date: Sept. 9, 2021

HealthScout AI summary: This trial targets adult patients with advanced solid tumors, including NSCLC, melanoma, liposarcoma, leiomyosarcoma, and SCCHN, who have exhausted standard treatments. It evaluates OR2805, a monoclonal antibody targeting CD163 to modulate tumor-associated macrophages, administered alone or with cemiplimab or docetaxel.

ClinicalTrials.gov ID: NCT05094804

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: BicycleTx Limited (industry) Phase: 1/2 Start date: July 17, 2020

HealthScout AI summary: This trial assesses BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, both as monotherapy and combined with pembrolizumab, in patients with advanced Nectin-4 expressing solid tumors such as urothelial carcinoma, breast, NSCLC, and ovarian cancers, who have progressed after prior treatment or lack standard therapy options. The study evaluates safety, pharmacokinetics, and preliminary efficacy, with previously reported promising response rates in treated urothelial cancer patients.

ClinicalTrials.gov ID: NCT04561362

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: A&G Pharmaceutical Inc. (industry) Phase: 1 Start date: Feb. 14, 2022

HealthScout AI summary: The trial investigates the use of AG01, an anti-progranulin/GP88 monoclonal antibody, in patients with relapsed or refractory advanced solid tumors, including triple negative breast cancer, hormone-resistant breast cancer, non-small cell lung cancer, and mesothelioma, who have no remaining effective treatment options. AG01 is administered biweekly to evaluate its safety, tolerability, and preliminary anti-tumor activity.

ClinicalTrials.gov ID: NCT05627960

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Eutilex (industry) Phase: 1/2 Start date: May 31, 2021

HealthScout AI summary: This trial is focused on patients with metastatic or locally advanced solid tumors, specifically colorectal cancer and non-small cell lung cancer, investigating the safety and efficacy of EU101, an agonistic monoclonal antibody targeting the 4-1BB receptor to enhance immune response.

ClinicalTrials.gov ID: NCT04903873

No known activity More information High burden on patient More information Started >3 years ago More information
Sponsor: Dragonfly Therapeutics (industry) Phase: 1/2 Start date: July 13, 2020

HealthScout AI summary: This trial targets patients with locally advanced or metastatic solid tumors, such as melanoma, non-small cell lung cancer, and triple-negative breast cancer, who have exhausted standard treatments, evaluating the safety and efficacy of DF6002, a monovalent IL-12 Fc fusion protein, both as a monotherapy and in combination with the PD-1 inhibitor Nivolumab. Eligible participants must have an ECOG performance status of 0 or 1 and adequate organ function.

ClinicalTrials.gov ID: NCT04423029

First Previous Page 39 of 40 Next Last
Please help us improve by giving us feedback or feature requests. Email [email protected]
Copy email address
Email copied to clipboard